Welcome to our dedicated page for 2Seventy Bio news (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2Seventy Bio stock.
2Seventy Bio Inc (TSVT) is a clinical-stage biotechnology company pioneering cell therapies for cancer treatment through innovative immuno-oncology research. This dedicated news hub provides investors and medical professionals with essential updates on the company’s scientific advancements and corporate developments.
Access real-time updates on clinical trial progress, regulatory milestones, and strategic partnerships shaping 2Seventy Bio’s pipeline of cellular therapies. Our curated collection includes earnings reports, research publications, and management commentary – all organized for efficient tracking of this precision medicine innovator.
Key coverage areas include novel therapy approvals, collaborative research initiatives with leading institutions, and analyses of the company’s position within the competitive cell & gene editing landscape. All content undergoes rigorous verification to ensure compliance with financial disclosure standards.
Bookmark this page for streamlined access to TSVT’s latest developments in cancer treatment innovation. Combine our news monitoring with Stock Titan’s analytical tools to maintain informed perspectives on this dynamic biotech enterprise.
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) announced that its management team will present at upcoming investor conferences, including the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and Citi’s 2024 Virtual Oncology Leadership Summit. The presentations will be available via live webcast and archived for 30 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
-
Rhea-AI Summary
Bristol Myers Squibb and 2seventy bio, Inc. announced that the FDA will convene a virtual meeting of the Oncologic Drugs Advisory Committee to review data supporting the supplemental Biologics License Application for Abecma for triple-class exposed relapsed or refractory multiple myeloma. The meeting will focus on the secondary endpoint of overall survival from the pivotal Phase 3 KarMMa-3 study. Abecma has recently been approved in Japan and received a positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use of the European Medicines Agency for patients with triple-class exposed relapsed and refractory multiple myeloma after at least two prior therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
-
Rhea-AI Summary
2seventy bio, Inc. (TSVT) announced a strategic re-alignment to focus exclusively on the commercialization and development of Abecma, its BCMA-targeted CAR T therapy for multiple myeloma. The company expects annual cost savings of approximately $150 million in 2024 and $200 million in 2025, extending its cash runway beyond 2027. 2seventy bio will sell its R&D pipeline to Regeneron to launch Regeneron Cell Medicines business. Chip Baird is named the incoming CEO, and Nick Leschly is named the incoming Chairman of the Board of Directors. The company will focus on Abecma's growth commercially and return to potential third-line launch later this year. The company is taking actions to return Abecma to commercial growth in 2024, expanding its site footprint to enable more patients to access the treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.9%
Tags
Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced results from the final progression-free survival (PFS) analysis of KarMMa-3, a Phase 3 study evaluating Abecma in adults with relapsed and refractory multiple myeloma. Abecma maintained a 51% reduction in risk of disease progression or death with a median PFS of 13.8 months compared to 4.4 months for standard regimens. The complete response rate was 44% vs. 5% for standard regimens. Abecma demonstrated deep and durable responses in newly-diagnosed multiple myeloma with a 77% complete response rate and no new safety signals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
-
Rhea-AI Summary
2seventy bio, Inc. (TSVT) to Host Conference Call Highlighting Data Presented at ASH Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
-
Rhea-AI Summary
2seventy bio, Inc. (NASDAQ: TSVT) reaffirms its dedication to maximizing shareholder value by considering all options to achieve this goal. The company is focused on making its therapies available to patients, driving value for shareholders, and supporting its employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
Rhea-AI Summary
Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.’s (Nasdaq: TSVT) outstanding shares, believes that the company could be conservatively worth ~$9 per share if it exclusively focuses on its most-valuable asset Abecma, reduces corporate overhead and makes improvements to the composition of the management team and board. The company is currently trading at a market capitalization of just $100 million, despite having a cash balance of $284 million and a 50% profit interest in Abecma that is likely worth at least a few hundred million dollars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
-
Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) will review data for the sBLA for Abecma for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on Phase 3 KarMMa-3 study. The ODAC meeting date is pending, and the PDUFA target action date has been extended. The companies await the FDA's decision and anticipate the ODAC to review data related to the secondary endpoint of overall survival (OS). The KarMMa-3 study showed significant improvement in progression-free survival (PFS) and a consistent safety profile of Abecma. Final PFS and interim OS data will be presented at the 2023 ASH Annual Meeting. Regulatory applications for Abecma in earlier lines of therapy are under review in Japan, Europe, and Switzerland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.31%
Tags
-
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) - Abecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of treatment. Abecma generated $69 million U.S. commercial revenue in the third quarter of 2023; $302 million U.S. commercial revenue year-to-date. Two solid tumor programs positioned to enter clinical trials in 2024. Ended quarter with $284.3 million cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) to announce Q3 2023 financial results and host conference call for business update. Participants can access the live webcast on the company's website. Replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
2Seventy Bio
Nasdaq:TSVT
TSVT Rankings
TSVT Stock Data
260.65M
48.67M
6.59%
85.1%
9.31%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE